INS and metabolic dysfunction-associated steatotic liver disease: Metformin prescribed in patients with NAFLD and T2DM causes weight loss, reduces liver transaminases, and improves hepatomegaly and IR or insulin secretion [14–16], whereas improvements in histology remain controversial [17, 18].